Controversies in upper GI oncology: first-line checkpoint inhibitor use in metastatic GEA: guided by PD-L1 CPS or not?

ESMO Open. 2023 Jun;8(3):101211. doi: 10.1016/j.esmoop.2023.101211. Epub 2023 Apr 11.

Authors

A Petrillo¹, S B Maron², R Sundar³

Affiliations

¹ Medical Oncology Unit, Ospedale del mare, Naples, Italy. Electronic address: angeli.petrillo@gmail.com.
² Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
³ Department of Haematology-Oncology, National University Cancer Institute, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

No abstract available

Publication types

Webcast

MeSH terms

Antineoplastic Agents, Immunological* / pharmacology
Antineoplastic Agents, Immunological* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
B7-H1 Antigen*
Humans

Substances

Antineoplastic Agents, Immunological
B7-H1 Antigen